[go: up one dir, main page]

WO2003049751A1 - Procede de fabrication d'une composition pharmaceutique utile pour combattre le cancer - Google Patents

Procede de fabrication d'une composition pharmaceutique utile pour combattre le cancer Download PDF

Info

Publication number
WO2003049751A1
WO2003049751A1 PCT/IB2002/005515 IB0205515W WO03049751A1 WO 2003049751 A1 WO2003049751 A1 WO 2003049751A1 IB 0205515 W IB0205515 W IB 0205515W WO 03049751 A1 WO03049751 A1 WO 03049751A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
mycobacterium
pharmaceutical composition
management
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2002/005515
Other languages
English (en)
Inventor
Bakulesh Mafatlal Khamar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2002353366A priority Critical patent/AU2002353366A1/en
Publication of WO2003049751A1 publication Critical patent/WO2003049751A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria

Definitions

  • This invention relates to the process of manufacturing a pharmaceutical composition useful for management of cancer.
  • Cancer is believed to be caused by defective immune system. Many attempts have been made to improve immune system without success. Surprisingly it is found that Mycobacterium w containing compositions which are useful in improving immune status in patients with leprosy are also useful in management of cancer. They are found to be useful in decreasing burden of disease and reducing symptoms associated with cancer. More surprising was their synergy with conventional therapy inspite of fact that they work through entirely different mechanism. Still surprising was decrease in side effects of other therapy rather than increase in overall side effects inspite of use in same therapeutic amount alongwith increase in effect.
  • BCG vaccine is used for boosting of immunity of individuals with cancer. This has not been well accepted as a mode of therapy due to inconclusive results.
  • the only accepted method of BCG is to use it for bledder cancer by way of intravesicular therapy.
  • the disadvantage associated with use of BCG is development of systemic and local tuberculosis caused by BCG. This is related to the fact that BCG contain live organism and they can be pathogenic to immunocompromised host.
  • US Patent 6,030,618 discloses an invention related to compositions, methods and kits for the prevention and treatment of primary and metastatic cancers and /or infectious diseases using heat shock/stress proteins (hsp) alone or in combination with each other and antigenic molecules to augment the immune responses to genotoxic and nongenotoxic factors, tumors, pathogens and infectious agents.
  • hsp heat shock/stress proteins
  • US Patent 5,767,156 provides a method of stimulating macrophage neutrophil and/or monocyte function in a subject.
  • the method involves the administration of an effective amount of a free fatty acid having 18 - 24 carbon chain length with 2-6 double bonds and TNF or a TNF fragment or GMCSF or interferon gamma.
  • US Patent 6,080,725 is directed to vaccines comprising one or more bacterial, viral, or tumour-associated antigens; and one or more saponin-lipophile conjugate in which the lipophilic moiety such as a lipid, fatty acid, PEG, or terpene is covalently bonded to a non-acylated or deacylated triterpene saponin via a carboxyl group present on the 3-O- glucuronic acid of the triterpene saponin.
  • the bacterial antigen in the vaccine are associated with a bacterial selected from diverse groups of bacteria including Mycobacterium tuberculosis.
  • US Patent 6,221,351 Bl relates generally to tumouricidal compositions and methods and more specifically to superantigens or enterotoxins derived from Staphlococcus aureus.
  • Peptides homologus to the enterooxins including shock syndrome ' toxin, Srreptococcal pyrogenic exotoxins, mycoplasma and mycobacterial species, minor lymphocyte stimulating antigens, heat shock proteins, stressYpeptides, mammary tumour virus peptides, homologous synthetic polypeptides, biochemically derivatised enterotoxins, genetically engineered enterotoxins and fusion proteins.
  • This invention also relates to superantigens expressed on the surface of lipid droplets in adjuvant-vehicle formulations or expressed in biologic cell surfaces as a result of enterotoxin gene transfection and used to produce a tumourocidal response in tumour bearing hosts. It also relates to enterotoxins and related compounds administered intravenously, subcutaneously, as in adjuvant form, or used extracorporeally in free or bound form to stimulate immunocytes, which are subsequently infused into tumour bearing tissues.
  • US Patent 6,090,385 discloses a method of treating a cancer patient which comprises administering to said patent an anti-tumour effective amount of at least, one of a water- soluble thermostable macromolecular antigen complex which is interspecific of microorganisms of the Mycobacteria, Nocardia, and Corynebacteria group and which exhibits after electrophoresis an innumo-electrophoretic precipitation pattern corresponding to that of the antigen complex 60 of the Mycobacterium bovis Clmette Guerin Bacillus strain, or immunogenic fragments of such a complex. It comprises an additional step of administering a therapeutic agent specific against the patient's cancer.
  • US Patent 6,056,964 suggests the delaying or preventing the growth oe spread of brest or bronchial neoplasm which comprises administering to a subject in need of the same, antigenic and/or immunoregulatory material whih comprises killed cells of Mycobacterium vaccae strain NCTC 11659 in an amount sufficient at least to delay or prevent the growth or spread of said neoplasm. This could be administered by intradermal injection.
  • US Patent 6,033,669 describes a method of stimulating the generation of cytotoxic T Cells (CTLs) in a patient, wherein the CTLs have the potential to destoy or attenuate cells presenting a characteristic disease-associated carbohydrate structure, which comprises administering to the patient an effective dose of a peptide/carbohydrate conjugate complex capable of generating cytotoxic T cell immunity against a carbohydrate structure, said conjugate structure comprising (i)a peptide component capable of binding an MHC class I molecule, and (ii) a carbohydrate component comprising of immunogenic specificity of said disease-associated carbohydrate structure and being of a size that enables a T cell receptor to encompass an epitope of said disease-associated carbohydrate structure.
  • CTLs cytotoxic T Cells
  • compositions containing Mycobacterium W are effective in the treatment of a broad range of cancer indications.
  • Pharmaceutical compositions as per present invention may contain extracts of Mycobacterium W alone or in combination of Mycobacterium W.
  • pharmaceutical composition may contain other immunomodulator. It can be administered in various ways including intradermal, oral, intralesional etc.
  • the present invention discloses such formulations and the method of their manufacture and use.
  • Mycobacterium W is a rapidly growing Mycobacterium which is not a pathogen.
  • Mycobacterium w is a non-pathogenic, cultivable, atypical mycobacterium, with biochemical properties and fast growth characteristics resembling those belonging to Runyons group IV class of Mycobacteria in its metabolic and growth properties but is not indentical to those strains currently listed in this group. It is therefore thought that (M w ) is an entirely new strain.
  • the species identity of M has been defined by polymerase chain reaction DNA sequence determination.
  • a pharmaceutical composition made from 'Mycobacterium w' (M w ) is found to be useful in the management of cancer.
  • M w Mycobacterium w'
  • the use of Mycobacterium w containing formulations is associated with decrease in burden of cancer tissue, decreasing symptoms associated with cancer and improving quality of life. It also improves tolerance to other therapies.
  • Therapeutic agent which may be used in the present invention resembles Mw a non-pathogenic, cultivable, atypical mycobacterium, with biochemical properties and fast growth characteristics resembling those belonging to Runyons group IV class of Mycobacteria in its metabolic and growth properties but is not indentical to those strains currently listed in this group. It is therefore thought that (M w ) is an entirely new strain.
  • Mw The species identity of Mw has been defined by polymerase chain reaction DNA sequence determination and differentiated from thirty other species of mycobacteria. It however differs from those presently listed in this group in on respect or the other. By base sequence analysis of a polymorphic region of pattern analysis, it has been established that M w is a unique species distinct from
  • the object of the present invention is to provide a pharmaceutical composition containing 'Mycobacterium w' (Mw) for the treatment of cancer.
  • Another object of the present invention is to provide a pharmaceutical composition containing'Mycobacterium w' (Mw) to improve quality of life in patient suffering from cancer.
  • Yet another object of the invention is to provide a pharmaceutical composition derived from mycobacterium w that are useful for the management of cancer.
  • Yet another object of present invention is to provide an a pharmaceutical composition containing 'Mycobacterium w' (Mw) which decreases burden of cancer cells/tissues of primary and/or secondary(metastatic), sensitive and/or refractory to conventional treatment.
  • Mw 'Mycobacterium w'
  • Yet another object of present invention is to provide a pharmaceutical composition which improves effect of conventional therapies.
  • Figure- 1 is X ray non small cell lung cancer before treatment - subject 1
  • Figure-2 is X ray non small cell lung cancer after treatment -subject 1
  • Figure-3 is X ray non small cell lung cancer before treatment - subject 2
  • Figure-4 is X ray non small cell lung cancer after treatment -subject 2
  • Figure-5 is CT Scan report of patient operated for colorectal cancer with liver metastatisis before treatment
  • Figure-6 is CT Scan report of patient operated for colorectal cancer with liver metastatisis after treatment
  • composition of a pharmaceutical composition the method of preparation, HPLC characteristic its safety and tolerability, methods of use and outcome of treatments are described in following examples.
  • HPLC characteristic its safety and tolerability
  • methods of use and outcome of treatments are described in following examples.
  • the following are illustrative examples of the present invention and scope of the present invention should not be limited by them.
  • Example 1 The pharmaceutical compositions:
  • Each dose of 0.1 ml of therapeutic agent contains:
  • Each dose of 0.1 ml of therapeutic agent contains: Mycobacterium w., (heat killed) 0.50 x 10 9 Sodium Chloride I. P. ... . 0.90% w/v
  • Each dose of 0.1 ml of therapeutic agent contains
  • Each dose of 0.1 ml of therapeutic agent contains
  • Each dose of 0.1 ml of therapeutic agent contains Acetone Extract of 1x10 10 Mycobacterium w
  • Each dose of 0.1 ml of therapeutic agent contains
  • Each dose of 0.1 ml of therapeutic agent contains
  • Mycobacterium w (heat killed) 0.5x10 7 _, .. . ... _ .. . .
  • Extract of mycobacterium w obtained 1x10 3 Mycobacterium w by disruption, solvent extraction or enzymatic extraction.
  • Example 2 The Process of preparing a pharmaceutical composition
  • Mycobacterium w is cultured on solid medium like L J medium or liquid medium like middle brook medium or sauton's liquid medium.
  • middle brook medium is enriched. It can be preferably enriched by addition of glucose, bactotryptone, and BSA. They are used in ratio of 20:30:2 preferably.
  • the enrichment medium is added to middle brook medium. It is done preferably in ratio of 15:1 to 25:1 more preperably in ratio of 20:1.
  • Bioreactor operation a) Preparation of vessel:
  • the inner contact parts of the vessel should be properly cleaned to avoid any contamination. Fill up the vessel with 0.1 N NaOH and leave as such for 24 H to remove pyrogenic materials and other contaminants. The vessel is then cleaned first with acidified water, then wit ordinary water. Finally, the vessel is rinsed with distilled water (3 times) before preparing medium. b) Sterilization of bioreactor
  • the bioreactor containing 9L distilled water is sterilized with live steam(indirect). Similarly the bioreactor is sterilized once more with Middlebrook medium.
  • the other addition bottles, inlet/outlet air filters etc. are autoclaved (twice) at 121°C for 15 minutes. Before use, these are dried at 50° C oven.
  • the pallet so obtained is washed minimum three times with normal saline. It can be washed with any other fluid which is preferably isotonic.
  • Pyrogen free normal saline is added to pallet. Any other pyrogen free isotonic fluid can be used as a pharmaceutical carrier.
  • the carrier is added in amount so as get to desired concentration of active in final form.
  • preservative is thiomesol which is used in final concentration of 0.01 % w/v.
  • Terminal sterilization can done by various physical methods like application of heat or ionizing radiation or sterile filtration.
  • Heat can be in the form of dry heat or moist heat. It can also be in the form of boiling or pasturisation.
  • Ionizing radiation can be ultraviolet or gamma rays or mircrowave or any other form of ionizing radiation.
  • mice The cultured organisms are infected to Balb/c mice. None of the mice should die and all should remain healthy and gain weight. There should not be any macroscopic or microscopic lesions seen in liver, lung spleen or any other organs when animals are killed upto 8 weeks following treatment. v.Biochemical Test:
  • the organism is subjected to following biochemical tests: a) Urease b) Tween 80 hydrolysis c) Niacin test d) Nitrate reduction test
  • the organism gives negative results in urease, tween 80 hydrolysis and niacin test. It is positive by nitrate reduction test.
  • the constituents of Mycobacterium w can be prepared for the purpose of invention by: I. Cell disruption II. Solvent extration III. Enzymatic extraction.
  • the cell disruption can be done by way of sonication or use of high pressure fractionometer or by application of osmotic pressure ingredient.
  • the solvent extraction can be done by any organic solvent like chloroform, ethanol, methanol, acetone, phenol, isopropyl alcohol, acetic acid, urea, hexane etc.
  • the enzymatic extraction can be done by enzymes which can digest cell wall/membranes. They are typically proteolytic in nature. Enzyme liticase and pronase are the preferred enzymes.
  • cell constituents of Mycobacterium w can be used alone in place of mycobacterium w organisms or it can be added to the product containing mycobacterium w.
  • Example 3 Characteristics of constituents of Mycobacterium w by HPLC analysis.
  • HPLC analysis was done using a waters system high performance liquid chromatography apparatus
  • Solvent A HPLC grade methanol.
  • Solvent B HPLC grade methylene chloride Binary gradient: The HPLC gradient initially comprised 9 ⁇ %(v/v) methanol (solvent B). The gradient was increased linearly to ⁇ 0%.
  • Example 4 Management of cancer refractory to standard treatment.
  • a 70 year old female suffering from multiple myeloma was receiving malphalan and prednisolone a therapy for 5 years. The desease recurred with bone pain. Her general condition was poor and she was berdridden. Her hemoglobin was reduced to 5.5. gm. She was put on intradermal injection of a pharmaceutical composition injection of a pharmaceutical composition containing mycobacterium w as per present invention. It was given as 0.1 ml intradermally over deltoid region at the interval of one weel. At the end of 3 months she is symptoms general condition has improved drastically and she is able to walk on her own. Her hemoglobin value has risen to 7.7 gm/dl from 5.5 gm/dl in absence of any specific treatment on anaemia.
  • the tumor was hormone independent and receptor status for estrogen and progesterone was negative.
  • she developed cough and breathlessness. It was found to be due to large metastatic lesion in her chest.
  • a pharmaceutical composition as per present invention was added to her therapy. At the end of three months, there was a remarkable improvement in her cough and breathlessness.
  • X-ray chest showed 25% decrease in size of metastatic lesion.
  • the mycobacterium w containing pharmaceutical cxomposition as per present invention was administered intradermally over deltoid region.
  • compositions containing Mycobacterium w(Mw) as per present invention are useful in treatment of cancer which are refractory to standard therapy. Their use is associated with amelioration of symptoms, improvement in general well being and quality of life, improvement in other associated conditions like anemia, neutropenia.
  • Example 5 Effect if o arnaceutical composition on cancer when used alone.
  • Superficial bladder cancer presents as hematuria. It is amenable to various forms of therapy. Drugs used to achieve remission are given intravesically e.g. doxorubinocin or BCG.
  • cystoscopically pharmaceutical composition as per present invention was given intradermally. It was given as 0.1 ml every month. By six weeks (after two injections) everybody became asymptomatic. Eight weeks later cystoscopy was performed. Surprisingly it was found that there was absence of any detectable lesion cystyoscopically. Six months followup did not reveal any recurrence of symptoms. Cystoscopy also revealed normal bladder mucosa with absence of detectable lesion.
  • Example 6 Effect of Mycobacterium w when radiotherapy is not adequate.
  • Muscle invasive bladder cancer (T 4 ) can be managed by radical cystectomy. However it is desirable to preserve bladder. Radiotherapy and/or chemotherapy are not adequate in achieving local control/remission of disease.
  • Example 7 Effect of Mycobacterium w when chemotherapy is not adequate.
  • Non small cell lung cancer is a small cell lung cancer.
  • Non small cell lung cancer is difficult to manage. It usually does not respond well to chemotherapy or radiotherapy. The response rate is inversely proportionate to extent of disease. In disease with extent T 4 surgery is not indicated and chemotherapy and/or radiotherapy has hardly any effect and carries poor prognosis.
  • Example 8 Effect of Mycobacterium w containing therapy on Quality of life and side effects of chemotherapy
  • mycobacterium w In a controlled study involving 20 patients with a breast cancer and_ bone metastasis effect of mycobacterium w was evaluated. All patients received chemotherapy in the form of cyclophosphamide, adriamycin and 5-fluorouracil. Mycobacterium w containing compositions were given as intradermal injections of 0.1 ml every wekk for two months followed by every 15 days for two months and monthly for two months for a total duration six months. 10 patients of 20 randemly received it while remaining 10 were kept as controls.
  • the chemotherapy induced hematological side effects resulted in postponement of chemotherapy in 2 out of 10 patients in treatment group and 5 out of 10 patients in control group.
  • mycobacterium w was useful in reducing side effects of chemotherapy.
  • Example 9 Use of Mycobacterium w in terminally sick patients with cancer.
  • Mycobacterium w was useful in ameliorating symptoms in terminally ill patient due to cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne le procédé de fabrication d'une composition pharmaceutique utile pour combattre le cancer. Selon l'invention, une composition pharmaceutique préparée à partir de 'Mycobacterium w' (Mw) est utile pour combattre le cancer. Nous avons découvert que le même agent thérapeutique est utile pour combattre le cancer. L'utilisation des formulations contenant 'Mycobacterium w' permet la diminution de la charge que représente les tissus cancéreux, l'atténuation des symptômes associés au cancer et l'amélioration de la qualité de vie; elle améliore aussi la tolérance des autres thérapies.
PCT/IB2002/005515 2001-12-10 2002-12-10 Procede de fabrication d'une composition pharmaceutique utile pour combattre le cancer Ceased WO2003049751A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002353366A AU2002353366A1 (en) 2001-12-10 2002-12-10 The process of manufacturing a pharmaceutical composition useful for management of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1166MU2001 2001-12-10
IN1166/MUM/2001 2001-12-10

Publications (1)

Publication Number Publication Date
WO2003049751A1 true WO2003049751A1 (fr) 2003-06-19

Family

ID=11097333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/005515 Ceased WO2003049751A1 (fr) 2001-12-10 2002-12-10 Procede de fabrication d'une composition pharmaceutique utile pour combattre le cancer

Country Status (2)

Country Link
AU (1) AU2002353366A1 (fr)
WO (1) WO2003049751A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765391A4 (fr) * 2004-06-07 2008-02-13 Gunn Harold David Compositions bacteriennes pour le traitement d'un cancer
JP2010522155A (ja) * 2007-03-20 2010-07-01 カディラ ファーマシューティカルズ リミテッド Ｐ３８阻害剤
JP2010531347A (ja) * 2007-06-28 2010-09-24 カディラ ファーマシューティカルズ リミテッド マイトジェン活性化プロテインキナーゼ調節剤
US8034359B2 (en) 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
WO2012117323A1 (fr) * 2011-02-28 2012-09-07 Cadila Pharmaceuticals Limited Vaccin thérapeutique contre le cancer
WO2013079980A1 (fr) * 2011-12-02 2013-06-06 Immodulon Therapeutics Limited Traitement immunogène du cancer
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
JP2014502631A (ja) * 2011-01-11 2014-02-03 カディラ ファーマシューティカルズ リミテッド 癌治療用医薬組成物
US8980279B2 (en) 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US10130692B2 (en) 2010-07-26 2018-11-20 Qu Biologics Inc. Immunogenic anti-inflammatory compositions
US10251946B2 (en) 2014-05-02 2019-04-09 Qu Biologics Inc. Anti-microbial immunomodulation
US10610578B2 (en) 2013-12-20 2020-04-07 Immodulon Therapeutics Limited Checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
US11207405B2 (en) 2015-06-24 2021-12-28 Immodulon Therapeutics Limited Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5513204A (en) * 1978-06-28 1980-01-30 Mitsui Toatsu Chem Inc Active compound having delayed allergic activity and anticarcinogenic activity, and its preparation
GB2236480A (en) * 1989-08-09 1991-04-10 Nat Inst Immunology Tuberculosis vaccine
US5336666A (en) * 1990-06-06 1994-08-09 Tsehay Neway Immunostimulant drug based on polar glyopeptidolipids of mycobacterium chelonae
WO1999032634A2 (fr) * 1997-12-23 1999-07-01 Genesis Research & Development Corporation Limited Compositions derivees de mycobacterium vaccae et leurs methodes d'utilisation
US6056964A (en) * 1995-03-29 2000-05-02 Stanford Rook Limited Immunotherapeutic agent and its use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5513204A (en) * 1978-06-28 1980-01-30 Mitsui Toatsu Chem Inc Active compound having delayed allergic activity and anticarcinogenic activity, and its preparation
GB2236480A (en) * 1989-08-09 1991-04-10 Nat Inst Immunology Tuberculosis vaccine
US5336666A (en) * 1990-06-06 1994-08-09 Tsehay Neway Immunostimulant drug based on polar glyopeptidolipids of mycobacterium chelonae
US6056964A (en) * 1995-03-29 2000-05-02 Stanford Rook Limited Immunotherapeutic agent and its use
WO1999032634A2 (fr) * 1997-12-23 1999-07-01 Genesis Research & Development Corporation Limited Compositions derivees de mycobacterium vaccae et leurs methodes d'utilisation

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US10086066B2 (en) 2004-06-07 2018-10-02 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
EP2286832A1 (fr) * 2004-06-07 2011-02-23 Harold David Gunn Compositions bactériennes pour le traitement du cancer
US9775896B2 (en) 2004-06-07 2017-10-03 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8034359B2 (en) 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
US9320788B2 (en) 2004-06-07 2016-04-26 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
AU2011200580B2 (en) * 2004-06-07 2012-09-27 Qu Biologics Inc. Bacterial compositions for the treatment of cancer
EP1765391A4 (fr) * 2004-06-07 2008-02-13 Gunn Harold David Compositions bacteriennes pour le traitement d'un cancer
US9320787B2 (en) 2004-06-07 2016-04-26 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
JP2010522155A (ja) * 2007-03-20 2010-07-01 カディラ ファーマシューティカルズ リミテッド Ｐ３８阻害剤
EP2131858A4 (fr) * 2007-03-20 2011-11-23 Cadila Pharmaceuticals Ltd Inhibiteurs de p38
GB2463434B (en) * 2007-06-28 2013-01-30 Cadila Pharmaceuticals Ltd Mitogen activated protein kinase modulator
EP2170083A4 (fr) * 2007-06-28 2011-09-28 Cadila Pharmaceuticals Ltd Protéine kinase activée par un modulateur mitogène
JP2010531347A (ja) * 2007-06-28 2010-09-24 カディラ ファーマシューティカルズ リミテッド マイトジェン活性化プロテインキナーゼ調節剤
US8980279B2 (en) 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation
US10130692B2 (en) 2010-07-26 2018-11-20 Qu Biologics Inc. Immunogenic anti-inflammatory compositions
JP2014502631A (ja) * 2011-01-11 2014-02-03 カディラ ファーマシューティカルズ リミテッド 癌治療用医薬組成物
US10335472B2 (en) 2011-02-28 2019-07-02 Cadila Pharmaceuticals Ltd. Therapeutic cancer vaccine
WO2012117323A1 (fr) * 2011-02-28 2012-09-07 Cadila Pharmaceuticals Limited Vaccin thérapeutique contre le cancer
US11219674B2 (en) 2011-02-28 2022-01-11 Cadila Pharmaceuticals Ltd. Therapeutic cancer vaccine
EP3424523A1 (fr) * 2011-02-28 2019-01-09 Cadila Pharmaceuticals Ltd. Vaccin thérapeutique contre le cancer
CN104023733A (zh) * 2011-12-02 2014-09-03 英模度伦医疗公司 癌症的免疫原性治疗
WO2013079980A1 (fr) * 2011-12-02 2013-06-06 Immodulon Therapeutics Limited Traitement immunogène du cancer
US11554166B2 (en) 2011-12-02 2023-01-17 Immodulon Therapeutics Limited Immunogenic treatment of cancer
US11318193B2 (en) 2011-12-02 2022-05-03 Immodulon Therapeutics Limited Immunogenic treatment of cancer
US10925952B2 (en) 2013-12-20 2021-02-23 Immodulon Therapeutics Limited Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapy
US10994002B2 (en) 2013-12-20 2021-05-04 Immodulon Therapeutics Limited Checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
US11000584B2 (en) 2013-12-20 2021-05-11 Immodulon Therapeutics Limited Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapy
US10610577B2 (en) 2013-12-20 2020-04-07 Immodulon Therapeutics Limited Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapy
US10610578B2 (en) 2013-12-20 2020-04-07 Immodulon Therapeutics Limited Checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
US12042532B2 (en) 2013-12-20 2024-07-23 Immodulon Therapeutics Limited Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapy
US10946083B2 (en) 2014-05-02 2021-03-16 Qu Biologies Inc. Anti-microbial immunomodulation
US10251946B2 (en) 2014-05-02 2019-04-09 Qu Biologics Inc. Anti-microbial immunomodulation
US11819543B2 (en) 2014-05-02 2023-11-21 Qu Biologics Inc. Anti-microbial immunomodulation
US11207405B2 (en) 2015-06-24 2021-12-28 Immodulon Therapeutics Limited Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapy

Also Published As

Publication number Publication date
AU2002353366A1 (en) 2003-06-23

Similar Documents

Publication Publication Date Title
CA1333152C (fr) Vaccin contenant des antigenes tumoraux et des adjuvants
WO2003049751A1 (fr) Procede de fabrication d'une composition pharmaceutique utile pour combattre le cancer
AU2002348738B2 (en) The method of treating cancer
JP2014512388A (ja) 免疫反応を増進するための組成物および方法
JPH08508976A (ja) 改善化免疫療法用組成物
CN1150388A (zh) 免疫治疗剂及其应用
US9056073B2 (en) Vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
Steenken Jr et al. Vaccinating properties of avirulent dissociates of five different strains of tubercle bacilli
ES2231037B1 (es) Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
WO2010031883A1 (fr) Agent immunothérapeutique convenant pour la prophylaxie primaire de la tuberculose
US11213555B2 (en) Intravenous injection for enhancing immune function
WO2003075824A2 (fr) Procede de fabrication d'une composition pharmaceutique s'utilisant contre la tuberculose
Julián et al. Bacteria-Derived Alternatives to Live Mycobacterium bovis Bacillus Calmette–Guerin for Nonmuscle Invasive Bladder Cancer Treatment
EP0644773B1 (fr) Complexe immunomodulateur anti-sida
US6806253B2 (en) Immunodulatory complex and use thereof in helicobacter diseases
WO2003075825A2 (fr) Procede applicable au traitement de la tuberculose
CA2474794A1 (fr) Procede relatif a la prophylaxie de la tuberculose chez des sujets porteurs du vih
CN109078177B (zh) 一种预防结核病的疫苗及联合用药物和制备方法、应用
CN120082471A (zh) 一种中药益生菌组合物及其在增强免疫力和/或抗肺癌中的应用
AU2003202725A1 (en) Method of providing prophylaxis for tuberculosis in HIV positive individuals
HK1138786A1 (en) Prophylactic tuberculosis vaccine
HK1138786B (en) Prophylactic tuberculosis vaccine
MXPA96004401A (es) Agente inmunoterapeutico y su uso

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP